Drug Overdose – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Drug Overdose – Pipeline Review, H1 2018’, provides an overview of the Drug Overdose pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Drug Overdose, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Drug Overdose

– The report reviews pipeline therapeutics for Drug Overdose by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Drug Overdose therapeutics and enlists all their major and minor projects

– The report assesses Drug Overdose therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Drug Overdose

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Drug Overdose

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Drug Overdose pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adapt Pharma Ltd

Crossject SA

Fab'entech SA

Icure Pharmaceutical Inc

Insys Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

PledPharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Drug Overdose Overview

Drug Overdose Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Overdose Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Overdose Companies Involved in Therapeutics Development

Adapt Pharma Ltd

Crossject SA

Fab'entech SA

Icure Pharmaceutical Inc

Insys Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

PledPharma AB

Drug Overdose Drug Profiles

Antibody for Poisoning, Drug Overdose and Opioid Addiction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

physostigmine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Alzheimer's Disease and Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug Overdose Dormant Projects

Drug Overdose Discontinued Products

Drug Overdose Product Development Milestones

Featured News & Press Releases

Mar 05, 2018: Adapt Pharma Expands Technical and R&D Teams

Feb 13, 2018: Aptar and Adapt Pharma Donate 5,000 Doses of NARCAN to Opioid Crisis Coalitions in Illinois

Feb 12, 2018: Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Dec 11, 2017: Mucodel Pharma Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation

Nov 14, 2017: Wisconsin Attorney General & University of Wisconsin System Partner with Adapt Pharma to Increase Access to NARCAN (naloxone HCl) Nasal Spray

Nov 03, 2017: Adapt Pharma Presents Human Factors Study Data on Usability of NARCAN (naloxone HCl) Nasal Spray at the 41st Association for Medical Education & Research in Substance Abuse Annual National Conference

Oct 24, 2017: Walgreens Stocking Life Saving Narcan Nasal Spray in All Pharmacies Nationwide

Oct 17, 2017: Adapt Pharma Launches Roll Call Training Video to Educate Law Enforcement on NARCAN (naloxone HCl) Nasal Spray 4mg

Oct 09, 2017: Adapt Pharma Announces Partnership with New York to Provide NARCAN (naloxone HCl) Nasal Spray 4mg

Oct 03, 2017: INSYS Therapeutics Completes Pharmacokinetics (PK) Study of Intranasal Naloxone for Opioid Overdose

Sep 15, 2017: Opiant Pharmaceuticals Provides an Update on NARCAN Nasal Spray

Aug 10, 2017: Opiant Pharmaceuticals Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization

Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent

Jun 18, 2017: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy for the Treatment of Local Anesthetic Systemic Toxicity

Jun 06, 2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose - Current Medical Research and Opinion Journal

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Drug Overdose, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Drug Overdose Pipeline by Adapt Pharma Ltd, H1 2018

Drug Overdose Pipeline by Crossject SA, H1 2018

Drug Overdose Pipeline by Fab'entech SA, H1 2018

Drug Overdose Pipeline by Icure Pharmaceutical Inc, H1 2018

Drug Overdose Pipeline by Insys Therapeutics Inc, H1 2018

Drug Overdose Pipeline by Klaria Pharma Holding AB, H1 2018

Drug Overdose Pipeline by Opiant Pharmaceuticals Inc, H1 2018

Drug Overdose Pipeline by PledPharma AB, H1 2018

Drug Overdose Dormant Projects, H1 2018

Drug Overdose Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Drug Overdose, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports